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Abstract
Regional anesthetics are often the preferred route for patients who are having orthopedic
shoulder procedures (Rai & Bhutia, 2017). Traditionally, plain local anesthetics, like
bupivacaine or ropivacaine, are used as the local anesthetic of choice because of their fast onset
and relatively predictable duration of action. However, several different additives have been
trialed to prolong the duration or improve the density of regional blocks. When looking at
additives to regional anesthetic techniques, side effects and duration of the block can be
unpredictable and unpleasant. For example, additives like fentanyl, morphine, and
dexamethasone have been trialed in regional techniques and have been shown to produce itching,
nausea and vomiting, respiratory depression, and hemodynamic instability (Rai & Bhutia, 2017).
Will adding dexmedetomidine to upper extremity regional anesthetic techniques produce
adequate anesthesia while reducing the incidence of side effects and the need for opioids in the
postoperative period?
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Efficacy of Dexmedetomidine as an Opioid Sparing Adjunct to Regional Anesthesia for
Shoulder Surgery
Shoulder surgery is one of the most painful procedures performed in the outpatient setting
(Hewson et al., 2019). With 7% of the general population and 26% of people over the age of 70
suffering shoulder pain, procedures on the shoulder are commonly performed to help alleviate
discomfort aggravated by strenuous movement, injury, or simple daily activities (Hewson et al.,
2019). Surgical intervention is often the optimal treatment when conservative management, like
physical therapy, fails to improve movement or pain (Karaman et al., 2018). Pain that occurs in
the immediate post-operative period, and the pain that occurs after discharge, can be a significant
source of distress and anxiety, which can negatively affect the healing and rehabilitation process
(Patel et al., 2020).
With an average numeric pain score of five on a scale of zero to 10, shoulder procedures
are notoriously uncomfortable in the post-operative period (Jung et al., 2017). Due to the severity
of pain reported, pain management can be challenging. Often, single analgesic regimens do not
adequately control the pain associated with recovery from a shoulder procedure (Patel et al.,
2020). Therefore, the use of narcotics has been a predominant post-operative pain management
technique for many years (Patel et al., 2020). A study by Gil et al. (2019) stated that 42% of
orthopedic surgeons prescribe opioids as the primary analgesic choice for post-operative pain.
The same study also examined the use of opioids after shoulder arthroscopies. Gil et al. (2019)
concluded that as high as 15% of patients remain on opioids to help ease their pain 180 days after
the completion of their procedure (Gil et al., 2019).
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While opioids may help alleviate pain, these drugs are not free of side effects. Short- and
long-term use of opioids can result in adverse side effects such as somnolence, respiratory
depression, constipation, nausea and vomiting, urinary retention, and opioid dependence (Patel et
al., 2020). Whether patients are younger with acute injuries or elderly with long-standing
shoulder pain, patients undergoing shoulder procedures may be opioid naïve, predisposing them
to more pronounced adverse side effects like respiratory depression, nausea, and vomiting. In
addition, patients who suffer from chronic pain requiring surgical intervention pose a challenge
as they may require higher than average dosing of an opioid to control their pain adequately.
Despite their pain control ability, the associated adverse effects can result in lengthened stays in
inpatient and recovery areas (Patel et al., 2020). Utilizing methods like peripheral nerve blocks to
avoid the use of opioids can help mitigate the adverse effects.
As an adjunct or alternative to opioid use, regional nerve blocks are often utilized as both
a method of surgical anesthesia and post-operative pain control (Karaman, 2018). When utilized
using plain local anesthetics, patients can benefit from an average of eight to 14 hours of pain
relief after their procedure (Jung et al., 2017). Single injection regional nerve blocks are good
analgesic techniques for short-term use, however, they may be inadequate to control pain that
persists for several days following shoulder surgery (Jung et al., 2017).
With success in pain control that nerve blocks provide, different medications have been
trialed as additives to extend the duration of these effects, providing more extended pain control
and relief after surgery. One medication trialed recently is dexmedetomidine, an alpha-2 receptor
agonist. Although dexmedetomidine has not been approved for perineural use by the United
States Food and Drug Administration (FDA), studies have shown that it may be efficacious in
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prolonging the duration of regional nerve blocks. The goal of this literature review is to examine
the efficacy of adjunct perineural dexmedetomidine on the duration of analgesia and the need for
opioids in the post-operative period.
Background
Shoulder Anatomy
The shoulder is a large, flexible joint of the upper body that is often prone to injury
(Karaman et al., 2018). The shoulder joint comprises two separate mobile joints consisting of
three bones and several different muscles that hold the joint together. These bones and muscles
work together to allow for a wide range of movements. The scapula and clavicle are articulated,
creating the acromioclavicular joint, and the humerus and scapula are articulated together to
create the glenohumeral joint. These two joints are held together by a group of four muscles, the
infraspinatus, supraspinatus, subscapularis, and teres minor muscles, called the rotator cuff.
These four muscles are attached to the humeral head by ligaments and stabilize the shoulder
joint. Together this group of muscles allows adduction, abduction, and rotation of the shoulder
joint. The deltoid, latissimus, and teres major muscles also facilitate joint mobility and stability
(Sheir et al., 2019).
Innervation of the shoulder originates from the anterior divisions of the spinal nerves at
the level of C5-T1. This group of nerves, also known as the brachial plexus, is further divided
into different sections: roots, trunks, divisions, cords, and branches. At the root level, the brachial
plexus is positioned between the anterior and middle scalene muscles, two muscles that are
important landmarks in successful regional nerve block placement (Okwumabua & Thompson,
2020). At the trunk level of the brachial plexus, the suprascapular nerve and the axillary nerve
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are responsible for both major motor and sensory innervation of the shoulder (Hewson et al.,
2019). The supraclavicular nerve, a branch of the cervical plexus at the level of C3-4, is
responsible for cutaneous sensory innervation for the shoulder (Hewson et al., 2019). Adequate
regional anesthetic techniques aim to block this set of nerves to provide post procedure
analgesia.
Shoulder Surgical Procedures
Multiple different surgical approaches can be utilized when shoulder surgery is
warranted. Most commonly, arthroscopic procedures are performed as they are less invasive and
are thought to have improved outcomes (Karaman et al., 2020). A surgeon can perform several
different procedures during an arthroscopic procedure through three to four small incisions
around the shoulder. Fluid is instilled into the joint through one of these incisions, inflating the
capsule and allowing visualization of structures via an arthroscope. Images are then projected
onto a screen where the surgeon and assisting team can surgically alter the shoulder joint and its
anatomical structures (Athwal, 2019). Rotator cuff repairs, tendon repairs, and shoulder
debridement are often completed via an arthroscopic approach (Athwal, 2019).
When arthroscopic approaches are not sufficient for surgical exposure, fully open or
mini-open procedures can be used to better access and visualize the shoulder joint and structures
in need of surgical repair. During a mini-open or open procedure, a surgical incision is created
over the shoulder joint to directly visualize and access the anatomical structures needed for
surgical intervention. Procedures that warrant an open procedure include total shoulder
replacements and certain rotator cuff repairs that are more technically challenging and warrant
more surgical exposure (Athwal, 2019). Unfortunately, regardless of the surgical approach, many
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of these patients suffer significant amounts of pain and often require high doses of opioids to
help control their pain level (Karaman et al., 2018).
Regional Nerve Blocks
Brachial Plexus Nerve Blocks
Interscalene blocks have been well studied and are considered the gold standard method
of regional anesthesia for upper extremity procedures (Patel et al., 2020). To perform an
interscalene block, brachial plexus nerves, which originate from C5-T1, are blocked by local
anesthetics at the nerve root level (Grant & Auyong, 2017). The patient is typically positioned
with the head of the bed elevated at 30 to 45 degrees. Their head is supported on a pillow and
turned facing away from the site of nerve block placement. The shoulder can be supported with a
rolled towel or pillow to facilitate extension of the neck and better exposure of procedural field.
The skin is then sterilized with a cleaning solution such as 2% chlorhexidine gluconate. Blood
pressure, oxygen saturation, and telemetry monitors are utilized throughout the nerve block
placement (Grant & Auyong, 2017).
Surgical analgesia and postoperative pain control can be achieved when local anesthetic
is deposited in the interscalene groove at the level of C5-C7 (Grant & Auyong, 2017). Under
ultrasound guidance, the nerves appear hyperechoic and can be identified in a “stoplight” like
arrangement between the anterior and middle scalene muscles (Grant & Auyong, 2017). This can
be seen below in Figure 1. Using the midpoint of the clavicle as a landmark, the subclavian
artery can be identified and used to help guide the ultrasound probe as it scans cephalad along
the neck to identify the brachial plexus. Typically, the brachial plexus is identified as two to
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three distinct dark circles surrounded by hyperechoic fascial layers three to five centimeters
above the clavicle at the level of the cricoid cartilage (Grant & Auyong, 2017).
Figure 1
Cadaver and Ultrasound Anatomy of Interscalene Regional Nerve Blocks

Note. Adapted from Gautier, P., Vandepitte, C., & Gadsden, J. (2021, October 4). Ultrasound-guided interscalene
brachial plexus nerve block. NYSORA. Retrieved February 10, 2022, from
https://www.nysora.com/techniques/upper-extremity/intescalene/ultrasound-guided-interscalene-brachial-plexusblock/

When the appropriate anatomy is identified, a four-inch echogenic needle is then

advanced through the skin and fascial layers in a medial and anterior direction using an in-plane
view technique to assure appropriate needle placement. Local anesthetic can be deposited when
the needle is appropriately positioned between the nerve roots. Proper needle placement can be
confirmed using nerve stimulation. A palpable twitch would be elicited with contact between the
nerve fiber and the stimulating needle, demonstrating the appropriate needle location. Ideally,
local anesthetic will surround and cause displacement of the nerves (Grant & Auyong, 2017). An
average of 20 to 25 milliliters (ml) of chosen local anesthetic is deposited to achieve complete
sensory and motor blockade (Ping et al., 2017). Repositioning the echogenic needle may be
necessary to thoroughly bathe and surround the nerve roots to achieve complete motor and
sensory block (Grant & Auyong, 2017).

DEXMEDETOMIDINE AND REGIONAL ANESTHESIA

9

Local Anesthetics
Mechanism of Action
Local anesthetics are commonly used to provide anesthesia and analgesia with both
surgical and nonsurgical use. There are two distinct classes, aminoamides, and aminoesters. Both
local anesthetics create a reversible ion conduction blockade that prevents impulse transmission
along central and peripheral nerves. Local anesthetics bind to specific alpha subunits within the
voltage gated sodium (Na+) channel to achieve this. When attached, local anesthetics block the
Na+ current across the cell membrane, reducing the excitability of the nerve fiber. The inhibited
influx of Na+ prevents the cell's ability to achieve threshold and fully depolarize. When unable
to reach threshold, the creation of an action potential within a nerve cell is hindered, reducing the
nerve cell’s ability to propagate action potentials (Rathmell, 2014). The absence of the ability to
propagate and transmit nerve impulses results in autonomic, somatic sensory, and somatic motor
nerve dysfunction producing the lack of sensation, skeletal muscle paralysis, and autonomic
dysfunction distal to the site of injection (Rathmell, 2014).
Onset & Duration
The duration of action of local anesthetics is directly correlated with lipid solubility and
the degree of protein binding (Irene et al., 2021). When a local anesthetic has a high degree of
lipid solubility and protein binding, the medication crosses a cell's protective lipid bilayer more
readily. After crossing into the cell, local anesthetics with a high degree of protein binding more
readily attach themselves to the structures of the voltage gated sodium channels, producing a
more prolonged blockade. For example, 0.5% ropivacaine and 0.5% bupivacaine, two
medications commonly used in peripheral nerve blocks, are 94 and 97% protein bound,
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respectfully, and produce a sensory nerve block duration of roughly eight to 14 hours (Ping et al.,
2017; Jung et al., 2017). This is in comparison to chloroprocaine, which has the lowest degree of
protein binding and lipophilicity, with an average action duration of two hours (Irene et al.,
2021).
Dexmedetomidine
First approved for intravenous use by the FDA in 1999, dexmedetomidine has become a
popular medication in both the intensive care unit and anesthesia practice. When given
intravenously, dexmedetomidine produces sedation and hypnosis that closely mimics natural
sleep without the respiratory depressive effects seen with other commonly used sedatives
(Weerink et al., 2017). However, several off-label uses have been described, including intranasal
use in pediatric sedation and perineural use in regional and neuraxial anesthesia techniques
(Weerink et al., 2017).
Dexmedetomidine is classified as a highly selective alpha-2 adrenergic receptor agonist
with sedative, sympatholytic, anxiolytic, and analgesic-sparing properties (Weerink et al., 2017).
With a half-life of two to three hours, the effects of dexmedetomidine are shorter than clonidine,
another alpha-2 agonist commonly used in anesthesia practices. Yet, the selectivity for alpha-2
receptors arguably makes the effects of dexmedetomidine more profound than clonidine Weerink
et al., 2017). Dexmedetomidine is greater than 90% protein bound and undergoes metabolism
almost exclusively in the liver.
Mechanism of Action
When used intravenously, dexmedetomidine produces analgesia and mild sedation by
directly stimulating alpha-2 receptors both centrally and peripherally. With an alpha-2 to alpha-1
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selectivity ratio of 220:1, dexmedetomidine has an extremely high affinity for alpha-2 receptor
mediated effects such as sedation and analgesia. Sedation is achieved through central stimulation
of alpha-2 stimulation in the locus coeruleus, which decreases norepinephrine release from the
presynaptic cleft via a negative feedback loop. Reduced levels of free norepinephrine result in a
reduced level of cyclic AMP, resulting in sympathetic nervous system depression and decreased
arousal (Weerink et al., 2017). In addition, alpha-2 stimulation inhibits the release of nociceptive
pain transmitters, like substance P and glutamate, in neurons at the dorsal root level, inhibiting
the nociceptive pathway preventing the transmission and amplification of pain signals traveling
to the brain (Weerink et al., 2017).
The mechanism of action of perineural dexmedetomidine is not well understood but is
thought to be multifactorial (Tripathi et al., 2016). When used peripherally, the stimulation of the
alpha-2 receptor by dexmedetomidine decreases the release of norepinephrine at the synaptic
cleft. This decrease in free norepinephrine produces an inhibitory effect on nerve action potential
transmission independent of the alpha-2 receptor itself (Tripathi et al., 2016). As the levels of
free norepinephrine decrease, the nerve’s ability to reach threshold and produce an action
potential is impaired, reducing the body’s ability to transmit pain signals from the periphery to
the brain (Weerink et al., 2017). Additionally, dexmedetomidine is described to produce
analgesia via directly binding to alpha-2 receptors in the central nervous system and spinal cord.
Hyperpolarization of sensory C, pain transmission alpha delta, and motor alpha-alpha fibers by
perineural dexmedetomidine suppress the ability to transmit pain impulses between nerve cells
(Weerink et al., 2017). Direct central stimulation of the locus coeruleus by dexmedetomidine is
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also thought to play a role in the analgesic effects of perineural dexmedetomidine (Weerink et
al., 2017).
Side Effects of Dexmedetomidine
Hemodynamic changes are commonly noted as side effects of intravenous
dexmedetomidine administration (Weerink et al., 2017). Hypertension is often seen with rapid
bolus administration. Bradycardia and hypotension are most described with continuous infusions.
These side effects are direct results of both pre-and postsynaptic alpha-2 receptor stimulation,
which causes vasoconstriction, vasodilatation, and reflex bradycardia (Weerink et al., 2017).
Decreased salivation, myocardial contractility, insulin release, and GI motility, have also been
described in the literature. The side effects noted with the perineural administration of
dexmedetomidine will be discussed later.
Literature Review
Methods
A literature search was performed on the following major databases: CINHAL, PubMed,
Cochrane Library, and Google Scholar. Randomized control trials (RCT), systemic reviews of
RCTs, and experimental studies published within the last five years, 2016-2021, were
preferentially selected. The search also revealed articles with lower levels of evidence, such as
quasi-experimental and non-experimental studies, literature reviews, case studies, and review
articles that were utilized to support the literature found. Initially, 25 articles were selected for
review. However, five articles were excluded due to duplicate studies and low levels of evidence.
Keywords for the initial search included “dexmedetomidine and shoulder surgery” which
provided various articles and multiple uses of dexmedetomidine used throughout the
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perioperative period. Further search terms were more specific and related to “dexmedetomidine
and brachial plexus block,” “perineural dexmedetomidine,” “interscalene + dexmedetomidine,”
“opioid + dexmedetomidine + shoulder surgery” which yielded more specific results related to
the research question.
From the literature review, several common themes were examined by various authors.
When analyzing the effectiveness of dexmedetomidine as an adjunct to local anesthetics used for
regional nerve blocks, the onset and duration of both sensory and motor blockade were heavily
scrutinized. The dosing of dexmedetomidine and the associated adverse side effects were also
reviewed extensively. Studies included in the literature review also examined the subjective
quality of sensory and motor block, pain scores, and opioid consumption in the post-operative
period, which will be explored in the following section.
Onset & Duration of Nerve Blocks with Dexmedetomidine
The onset of sensory and motor blocks has been well studied over the last five to 10
years. Dai et al. (2018) conducted a systematic review and meta-analysis of 12 different
independent studies that examined the efficacy of dexmedetomidine used in conjunction with
ropivacaine in brachial plexus blocks. From their review, Dai et al. (2018) elucidated that the
addition of dexmedetomidine hastened the onset of both sensory and motor block. The study
showed that sensory block onset was decreased by an average of 3.86 minutes (CI = 95% -5.45
to -2.27 minutes, I=85%, p <0.00001), and motor block onset time was decreased by 5.21
minutes (CI =95%, 7.48 to 2.94 minutes, I2 = 94%; p < .0001) (Dai et al., 2018).
The study also examined each nerve block approach (interscalene, supraclavicular,
infraclavicular) that was utilized and determined from the data that despite the different

DEXMEDETOMIDINE AND REGIONAL ANESTHESIA

14

approaches, the addition of dexmedetomidine consistently decreased the time to onset (Dai et al.,
2018).
As mentioned above, Dai et al. (2018) examined multiple aspects of the benefits of
adding dexmedetomidine to brachial plexus blocks. Their study also examined the duration of
both sensory and motor block duration. When added to 0.5% ropivacaine, dexmedetomidine
facilitated an average of 228.7 minutes of additional sensory block (CI=95% 187.87–269.52
minutes, I2 = 93%; p < .0001) (Dai et al., 2018). Similarly, motor block duration was also
extended by dexmedetomidine. Motor blockade was shown to have been prolonged by an
average of 191.7 minutes (CI=95 152.48–230.91 minutes, I2 = 92%; p < .0001) (Dai et al.,
2018).
Interestingly, the block approach with the most significant extension of motor blockade
was noted to be the supraclavicular approach more than any other approach studied. Also, the
data from Dai et al. (2018) showed that dosing of 50 micrograms (mcg) of dexmedetomidine or
higher, prolonged motor blockade, but not as effectively as dosing less than 50 mcg (165.2
minutes vs. 337.2 minutes respectively) (Dai et al., 2018). The authors further say that this
significant difference may be related to the amount of 0.5% ropivacaine utilized more than the
dosing of dexmedetomidine as an adjunct (Dai et al., 2018).
Somsunder et al. (2019) conducted a study comparing the effects of intravenous
dexmedetomidine and perineural dexmedetomidine used in combination with 0.5%
levobupivacaine administered in a brachial plexus block. The study examined a difference in the
onset and duration of both sensory and motor deficits. The study concluded that intravenous
dexmedetomidine at 1 mcg/kg was administered 10 minutes before block placement and
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perineural dexmedetomidine administered at 1 mcg/kg in the brachial plexus block produced
similar results. The intravenous group produced sensory and motor blocks at 7.58 ± 1.6 min and
9.22 ± 2.6 min, respectively (Somsunder et al., 2019). The perineural group produced a mean
duration of sensory and motor blocks onset of 7.06 ± 2.0 min and 10.10 ± 2.83 min, respectively
(Somsunder et al., 2019). The marginal difference in recorded times to onset was deemed
statistically insignificant by the authors, signifying that the two methods of administration were
comparable in their effects, and one was not superior to the other (Somsunder et al., 2019).
Hussain et al. (2017) also examined the effects of dexmedetomidine on the onset of
sensory block. Their meta-analysis reviewed 18 different randomized control trials with 1092
patients enrolled. Their analysis of the data also showed an average decrease in the time to
sensory block of 3.19 minutes (Hussain et al., 2017). The time to motor block onset was also
shorted by an average of 2.92 minutes (Hussain et al., 2017). The data further supports the idea
that that as an adjunct, dexmedetomidine decreases the time to sensory and motor blockade.
Hussain et al. (2017) also examined the overall duration of sensory and motor block with
dexmedetomidine utilized as an additive to local anesthetics. Their study showed that adding
dexmedetomidine to local anesthetic to be administered into a brachial plexus blocks
significantly prolonged the duration of both sensory and motor block by as much as 261.41
minutes and 200.9 minutes, respectively (Hussain et al., 2017).
Ping et al. (2017) conducted a meta-analysis of 18 studies, with a total of 1015 patients,
that examined the duration of sensory block. Total time was calculated as the time from
administration of local anesthetic with complete sensory block to complete sensory recovery.
The study revealed an estimated prolongation of sensory block by 282.65 minutes when
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dexmedetomidine was used as an adjunct to long-acting local anesthetics and 60.16 minutes with
intermediate-acting local anesthetics (Ping et al., 2017). The study also showed that the nerve
block type showed some heterogenicity. The infraclavicular nerve block technique showed that
the duration of sensory prolongation was predictable and reproducible with a heterogenicity of
I2=0% (Ping et al., 2017). Axillary and supraclavicular approaches showed prolongation of
sensory block, but with heterogenicity of I2=68.4% and I2=95.9%, respectively (Ping, 2017).
The variation in results is considerable, yet further examination and meta-analysis of bias and
effects by Ping et al. (2017) determined the heterogenicity did not affect the quality and
predictability of the results. From the data, Ping et al. (2017) concluded that despite the block
technique, dosing, and local anesthetic of choice, dexmedetomidine prolonged the analgesic
effects of peripheral nerve blocks by as much as seven hours, producing a total time of analgesia
as long as 24 hours, compared to the estimated eight to 14 hours of when plain local anesthetic is
administered (Ping et al., 2017).
Similarly, Agarwal et al. (2014) studied the effects of dexmedetomidine as an adjunct to
local anesthetics in brachial plexus blocks. Their study produced similar results to the studies
mentioned above. The control group of 25 patients received plain 0.325% bupivacaine in their
study. The experimental group of 25 patients received 0.325% bupivacaine and a standard dose
of 100 mcg of dexmedetomidine. The onset of both sensory and motor block was significantly
shorter in the experimental group when compared to the control group (Agarwal et al., 2014).
The time to onset of sensory block in the experimental group was nearly eight minutes shorter
(13.20±1.848, t= -7.911, p < 0.001) than the plain local anesthetic control group (19.04±3.195)
(Agarwal et al., 2014). Similarly, the onset to motor block in the experimental group was shorted
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by almost 10 minutes (16.3±1.7, t= -9.6, p < 0.001) when compared to the control group time to
motor block onset (22.7±2.8) (Agarwal et al., 2014).
Duration of action was also assessed in the study by Agarwal et al. (2014). The data
collected from the 50 patient, randomized control trial showed sensory and motor blockade
lasting an average of 700 minutes in the experimental group (Agarwal et al., 2014). The control
group duration was noted as an average of 200 minutes (Agarwal et al., 2014). Duration of
analgesia was also examined and showed similar results. Duration of analgesia in the
experimental group lasted almost 500 minutes longer, clocking at 776.4 minutes compared to the
plain local anesthetic group averaging 241.4 minutes (Agarwal et al., 2014). Again, that data
supports the idea that dexmedetomidine helps prolong regional blocks' analgesic effects.
However, limitations of the study were the small sample size and patient population without
significant comorbidities, warranting additional research in a wider variety of patients to help
further validate the results of the study.
A study of a similar design to Agarwal et al. (2014) was conducted by Manjunatha et al.
(2020). In the Manjunatha et al. (2020) trial, 70 patients were enrolled. Each patient received an
ultrasound-guided supraclavicular block for an upper extremity surgery. The experimental group
received 20 ml of 0.25% bupivacaine with 1 mcg/kg of dexmedetomidine. The control group
received 20 ml of 0.25% bupivacaine only. Similar results were yielded. Onset was noted to be
quicker with the addition of dexmedetomidine; however, the study does not delineate specific
measurements (Manjunatha et al., 2020).. In addition, the duration of both sensory and motor
block was substantially prolonged almost twice as long in the experimental group (863.8 ± 106.8
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min and 758. 5 ± 121.6 min) compared to the control group (335.6 ± 58.6 min and 308.4 ± 71.8
min) (Manjunatha et al., 2020).
Dosing of Dexmedetomidine in Nerve Blocks
Several studies examined the dosage of dexmedetomidine as an adjunct to regional
anesthetic techniques. When examining non-weight-based dosing, several studies investigated
the effects of dexmedetomidine in doses less than or greater than 50 mcg per regional block. Dai
et al. (2018) completed a systematic review of 12 different studies, with a patient population of
617, that analyzed the effects of dexmedetomidine as an adjunct to upper extremity regional
anesthetic techniques. From the pooled data, Dai et al. (2018) elicited dosing of
dexmedetomidine greater than 50 mcg added to ropivacaine produced a longer duration of both
sensory and motor block when compared to doses of 50 mcg or less. The study also stated that
the duration of analgesia was prolonged with a mean difference of an additional 303.04 minutes
with a confidence interval of 95% (228.84–377.24 minutes) and a degree of heterogenicity of
85% (Dai et al., 2018).
Like Dai et al. (2018), Hussain et al. (2017) investigated the efficacy of dexmedetomidine
as an adjunct of regional anesthesia. They examined dosing in increments of less than or greater
than 50 mcg compared to a control group with plain local anesthetics. The study shows that
doses greater than 50 mcg added to various local anesthetics prolonged sensory and motor block
and decreased the onset of both sensory and motor blocks, leading to an overall increase in the
duration of regional block compared to plain local anesthetics (Hussain et al., 2017). The study
also showed that hemodynamic effects were more prevalent in the group with dosing greater than
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50 mcg. Still, the hemodynamic changes were not significant enough that additional or more
invasive hemodynamic monitoring was necessary (Hussain et al., 2017).
Two independent studies by Vorobeichik et al. (2017) and Rao & Rajan (2021)
investigated the use of dexmedetomidine in regional anesthetic techniques and yielded similar
results. Vorobeichik et al. (2017) conducted a systematic review and meta-analysis of 32
different trials examining the effects of perineural dexmedetomidine. Their study supports the
idea that dexmedetomidine added to regional blocks increased duration of action and decreased
time to onset of both motor and sensory block. The study concluded that a dose between 50 and
60 mcg maximized the benefits of dexmedetomidine as an additive while mitigating the adverse
hemodynamic effects, like bradycardia and hypotension, reported with greater dosing
(Vorobeichik et al., 2017).
Rao & Rajan (2021) also examined the effects of dexmedetomidine in peripheral nerve
blocks. They analyzed data from 34 studies with a pool of 2007 patients. Their research and
analysis supported the dosing of 50 to 60 mcg of dexmedetomidine used as an adjunct in
peripheral nerve blocks. Their examination of the available data also showed that 50 to 60 mcg
added to peripheral nerve blocks maximized the sensory blockade without hemodynamic
instability reported with higher dosing (Rao & Rajan, 2021).
Jung et al. (2017) examined the effects of various weight-based dosing of
dexmedetomidine as an additive to interscalene blocks for patients undergoing arthroscopic
shoulder surgery. Ninety-seven patients were enrolled in a trial and then divided into four test
groups. The control group was administered 20 ml of 0.5% ropivacaine with 2 ml of normal
saline. The three trial groups were administered 20 ml of 0.5% ropivacaine with weight-based
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dosing of 1 mcg/kg, 1.5 mcg/kg, and 2 mcg/kg of dexmedetomidine, respectively. Dosing
calculations utilized ideal body weight via the Broca calculation of IBW= Height (cm) – x,
where x = 100 for men and 105 for women. In this study, brachial plexus blocks were utilized as
postoperative pain control rather than the primary anesthetic technique as each patient underwent
general anesthesia after regional block placement.
The study by Jung et al. (2017) revealed incremental increases in dosing produced
hemodynamic changes that were more significant in the trial dexmedetomidine groups versus the
control groups. From the study, there was no significant difference in the block duration in
groups one and two, 1 mcg/kg and 1.5 mcg/kg. Group three, which received 2 mcg/kg of
dexmedetomidine, showed more significant, transient episodes of hypotension; however, the
duration and pain control quality of the block lasted as much as three hours longer than group
two (1.5 mcg/kg) and the overall duration of the block lasted up to 20 hours (Jung et al., 2017).
The authors identified several limitations to this study. They mention that the American Society
of Anesthesiology (ASA) physical status classification and total body weight were higher in the
trial group than in the control group. With higher ASA physical status classifications in the
control group, patients typically have significant comorbidities, like obesity, that may affect the
metabolism of medications used in the trial. To help negate that observation, ideal body weight
was used to calculate all perineural dexmedetomidine administrations (Jung et al., 2017).
A study by Thakur et al. (2017) examined the effects of dexmedetomidine at doses of 0.5
and 1 mcg/kg added to 2% lidocaine for patients receiving axillary nerve blocks. Their study
enrolled 104 patients divided into three equal-sized groups: one control and two trial groups.
When looking at the data gathered from the study, the addition of both 0.5 and 1 mcg/kg of
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dexmedetomidine used in conjunction with 2% lidocaine prolonged the duration of analgesia by
as much as 395.9 minutes (Thakur et al., 2017). When comparing the control group, that received
plain 2% lidocaine to the two trial groups that received 0.5 and 1 mcg/kg of dexmedetomidine,
the study showed that the addition of dexmedetomidine prolonged the time until the request for
the first dose of supplemental analgesics in both experimental groups. In the 0.5 mcg/kg group,
30% required additional analgesia in the first six hours after their procedure (Thakur et al.,
2017). Eighty percent of patients who received 1 mcg/kg of dexmedetomidine as an additive to
their axillary block required analgesics in the six-hour post-operative period. Despite the need for
rescue analgesics, both groups required less than the plain 2% lidocaine group, where 100% of
patients in that group analgesics needed within the first six hours post operatively (Thakur et al.,
2017). A limitation of this study was the lack of ultrasound. The authors noted that ultrasound
may have helped facilitate a better block placement and a reduction in the total volume of 2%
lidocaine used to achieve adequate analgesia (Thakur et al., 2017).
Quality of Analgesia
In a study by Tripathi et al. (2016), perineural dexmedetomidine was compared to
perineural clonidine in ultrasound-guided brachial plexus blocks. In this study, 60 patients were
enrolled and divided randomly into two, 30 patient groups. The control group received 1 mcg/kg
of clonidine, and the experimental group received 1 mcg/kg of dexmedetomidine. Both groups
received 39 ml of 0.25% bupivacaine as a local anesthetic in the peripheral block. Tripathi et al.
(2016) defined the quality of analgesia on a one to four scale with the following score
definitions: a score of one signified unsuccessful block placement, a score of two was correlated
with moderate pain complaints from the patient that required supplemental analgesia, a score of
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three was correlated with minor complaints of discomfort that required supplemental analgesia,
and a score of four was associated with no complaints and ‘excellent analgesia’ (Tripathi et al.,
2016). Data from the study suggests that the addition of dexmedetomidine to 0.25% bupivacaine
produced more satisfactory and higher quality analgesia, with 80%, 24 of the 30 participants,
scoring a four on the quality scale (Tripathi et al., 2016). A total of six members of the
dexmedetomidine group scored a three on the quality scale. In comparison, members of the
clonidine group did not score as highly, with 60%, 18 of 30 participants, scoring a three on the
quality scale. The remaining 40%, 12 of 30 participants, did score a four. Although the study’s
sample size was small, the data collected supports dexmedetomidine as the superior additive
choice to help improve the overall quality of peripheral nerve block anesthesia (Tripathi et al.,
2016).
Rao & Rajan (2021) examined the efficacy of dexmedetomidine as an additive to
peripheral and neuraxial nerve blocks. A meta-analysis of 18 independent studies supported that
the addition of dexmedetomidine to peripheral nerve blocks improved the overall quality and
analgesia of peripheral nerve blocks compared to plain local anesthetics (Rao & Rajan, 2021).
However, criteria to define the quality of peripheral nerve blockade were not defined by the
study.
Pain Scores & Rescue Analgesic Use
Hussain et al. (2017) examined the total analgesic consumption during the 24-hour period
following a patient’s procedure. Their meta-analysis uncovered that the need for rescue or
supplemental analgesics in the immediate postoperative period was reduced in the
dexmedetomidine trial group compared to plain local anesthetics (Hussain et al., 2017). Hussain
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et al. (2017) demonstrated data extracted from several studies included in their meta-analysis,
showing the difference in analgesic consumption over the first 24-hour postoperative period in
Table 1 below.
Table 1.
Individual Study Data for Postoperative Pain with the Use of Dexmedetomidine Versus Control
at 24-Hour Follow-Up

Note. Adapted from “Optimal Dose of Perineural Dexmedetomidine for Interscalene Brachial Plexus Block to
Control Postoperative Pain in Patients Undergoing Arthroscopic Shoulder Surgery. A Prospective, Double-Blind,
Randomized Controlled Study” by Hussain et al., 2017, Regional anesthesia and pain medicine, 42(2), 184–196.

As shown in Table 1 above, several studies examined by Hussain et al. (2017) supported
the idea that using dexmedetomidine as an adjunct to peripheral nerve blocks reduced the overall
consumption of analgesics 24 hours after surgery. However, the studies examined by Hussain et
al. (2017) utilized several different postoperative analgesics and pain rating scales, making it
challenging to conclude dexmedetomidine’s effectiveness at decreasing pain scores and the need
for rescue analgesics in the postoperative period. Despite being unable to pool the data they
collected, Hussain et al. (2017) mentioned in their analysis that five of their 12 selected studies
show a decreased requirement for postoperative analgesics in the 24 hours post-procedure in the
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trial groups that received dexmedetomidine as an adjunct to local anesthetic when compared to
the control of plain local anesthetics (Hussain et al., 2017). Three of the 12 studies showed no
difference in pain scores or need for analgesics between trial and control groups (Hussain et al.,
2017).
Jung et al. (2017) also assessed pain scores and the need for rescue analgesia in the
postoperative period. From their study of 90 patients, the data collected showed that pain scores
on the numeric pain scale were lower in the trial groups treated with perineural dexmedetomidine
compared to the placebo control group treated with plain local anesthetics at 12 and 18 hours
after surgery. However, there was no reported difference in pain scores or need for analgesics 24
and 36 hours postoperatively (Jung et al., 2017). They concluded that although perineural
dexmedetomidine extended the duration of action and sensory blockade, numeric pain scores in
both the trial and control group were similar at the 24-hour mark and that multimodal analgesia
should be utilized before the pain control efficacy of the nerve block wears off (Jung et al.,
2017).
Vorobeichik et al. (2017) conducted a systematic review of 34 separate studies, with a
patient population of 2007 patients, investigating the efficacy of dexmedetomidine as an adjunct
to brachial plexus blocks. Of those 34 examined trials, 26 trials examined local
anesthetic/dexmedetomidine peripheral nerve block analgesic outcomes. Cumulative 24-hour
analgesic consumption was reported directly in eight of the 34 trials. When combined with local
anesthetics, dexmedetomidine decreased the oral morphine equivalent consumption by an
average of 10.2 milligrams (mg) (95% CI [-15.3, -5.2], (p < 0.0001, I2 1⁄4 83%) (Vorobeichik et
al., 2017).
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Pain rating scores were also scrutinized by Vorobeichik et al. (2017). Seven of the 34
trials looked at pain scores 24 hours after surgery. The limited number of studies reported a
slight decrease, less than one point on a zero to 10 pain rating scale (Vorobeichik et al., 2017).
Overall, there were several limitations to the study by Vorobeichik et al. (2017). The definition
of duration of analgesia varied, including time to first analgesic request, time to pain score
greater than three or four on a scale of 0-10, or time to patient reporting surgical site pain. The
inconsistency in measurement scales was a limitation of the study as the frank variation from
study to study made it difficult to draw concrete conclusions (Vorobeichik et al., 2017).
El-Boghdadly et al. (2017) also included an examination of the postoperative analgesic
requirement. Their study examined the difference between clonidine and dexmedetomidine used
perineurally in brachial plexus blocks. Their meta-analysis of 14 different studies examined a
patient population of 868 patients. Like the studies mentioned above, El-Boghdadly et al. (2017)
found inconsistencies in how the individual studies reviewed report pain scores and analgesic
consumption, proving a limitation of the overall study. However, the duration of analgesia was
assessed in 12 of the 14 studies included in their meta-analysis. El-Boghdadly et al. (2017)
concluded that compared to clonidine, dexmedetomidine prolonged total analgesic effect by a
factor of 1.2 providing a longer duration of complete analgesia (p < .00001). The authors inferred
that the prolonged analgesic effects might reduce the overall need for rescue and supplemental
analgesics in the postoperative period (El-Boghdadly et al., 2017).
Dai et al. (2018) also examined pain scores in the postoperative period. Unfortunately,
the data pool utilized multiple different pain rating scales. The authors felt that not enough data
was collected using one pain scale to conduct an appropriate comparison, proving to be a
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limitation of the study. However, the overall trend from the data examined does reflect the idea
dexmedetomidine reduced pain scores and the consumption of postoperative opioids (Dai et al.,
2018).
Side Effects of Dexmedetomidine in Nerve Blocks
As an alpha two adrenoceptor agonist, dexmedetomidine’s side effect profile has been
well described. Intravenous dexmedetomidine has the potential to cause transient hypertension
with rapid bolus administration, bradycardia, and hypotension (Weerink et al., 2017). Asku &
Bicer (2017) examined the off-label use of dexmedetomidine as an additive to brachial plexus
blocks as a means of reducing the total volume of local anesthetic needed to achieve surgical
anesthesia. From their study of 50 patients, several different side effects were recorded. Between
the control and the trial group, changes in heart rate and blood pressure were noted in the trial
group only. Heart rates were recorded in five, 10, and 15-minute intervals for the first 120
minutes after block placement. In the trial group, statistically significant decreases in heart rate
from basal heart rate were noted for the first 90 minutes after block placement (p < 0.05) (Asku
& Bicer, 2017). In the trial group, heart rates were reported to decrease from 77.5 ± 14.5 to a
range of 66.5 ± 8.9 at the 60-minute mark. Heart rates averaged in the mid 60’s for the first 90
minutes after block placement (Asku & Bicer, 2017). No significant changes in heart rate were
observed in the control group (Asku & Bicer, 2017).
Mean arterial blood pressure (MAP) values were recorded at similar intervals, however
statistically significant decreases in MAP were not as prevalent (p <0.1). The basal MAP reading
for both the control and the experimental group averaged 100 ± 16.0 (Asku & Bicer, 2017). With
the addition of dexmedetomidine, MAP readings dipped slightly to 92.1 ± 14.8, at the 15-, 60-,
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and 90-minute intervals after block placement (Asku & Bicer, 2017). At no point were these
hemodynamic changes noted to be outside of normal hemodynamic parameters but were
decreased from the basal readings before placement of the brachial plexus block (Asku & Bicer,
2017).
Another study that examined the hemodynamic effects of dexmedetomidine as an
additive to regional anesthetics was by Nazir & Jain (2016). Their study consisted of 70 patients,
all of whom were ASA I or II, undergoing upper extremity surgeries. All 70 patients received an
ultrasound-guided supraclavicular block with 38 ml of 0.25% bupivacaine. The control group
received plain local anesthetic and the experimental group 1 mcg/kg of dexmedetomidine in
addition to the 0.25% bupivacaine. Basal heart rates were recorded before block placement in
each member of both groups. Heart rates were measured at various intervals for the first 150
minutes after block placement. In the experimental group, heart rates were noted to be decreased
from baseline as many as 15 to 20 beats per minute at the 15 through 90-minute measurements
(Nazir & Jain, 2016). During the study, no patient became dangerously bradycardic necessitating
emergent intervention as noted in other studies, such as the study by Ping et al. (2017). At the
120-minute measurements, heart rates in both the experimental group returned to near basal rates
and were similar to those documented in the control group. No significant changes in heart rate
were noted in the control group (Nazir & Jain, 2016).
Discussion
As an adjunct to regional anesthesia for shoulder surgery, the literature supports
dexmedetomidine as a method of extending both the sensory and motor blockade achieved by
local anesthetics used in regional anesthesia. Dai et al. (2018), Ping et al. (2017), and Hussain et
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al. (2017) all concluded that the inclusion of dexmedetomidine in regional blocks both hastened
the onset of motor and sensory block by an average of three minutes, and it extended the duration
of both blocks by an average of 220 minutes. Agarwal et al. (2014) conducted a similar
experiment which concluded that using dexmedetomidine and 0.325% levobupivacaine extended
the duration of regional blocks by an average of 500 minutes, for a total duration of 700 minutes.
Each study yielded evidence supporting dexmedetomidine’s efficacy for extending the period of
sensory and motor blocks and providing extended pain relief for patients.
The dose of dexmedetomidine did influence the duration of pain relief gained. Dai et al.
(2018) and Hussain et al. (2017) examined dosing less than and greater than 50 mcg of
dexmedetomidine in a regional block. The study showed that dosing above 50 mcg had a better
efficacy for extending the durational analgesic effect. A meta-analysis by Vorobeichik et al.
(2017) also supported dosing above 50 mcg. Vorobeichik et al. (2017) concluded that the optimal
dose to achieve the maximal prolongation of pain relief without adverse side effects is 50 to 60
mcg. Weight based dosing was also examined. Jung et al. (2017) examined weight-based dosing
in increments of 1.0, 1.5, and 2.0 mcg/kg added to regional blocks. The study concluded that the
optimal dose to achieve the maximal benefits of dexmedetomidine was 1.5 mcg/kg, which
produced pain relief for an additional three hours without negative side effects such as
hypotension and bradycardia (Jung et al., 2017).
Several studies examined the efficacy of perineural dexmedetomidine as an opioid
sparing technique. For example, Hussain et al. (2017) examined the total consumption of
analgesics in the 24-hour post-operative period in patients who received dexmedetomidine as an
adjunct to their regional nerve blocks. Their meta-analysis concluded that the experimental
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groups that received adjunct dexmedetomidine consistently consumed a lower amount of both
opioid and non-opioid rescue analgesics immediately after the procedure and in the first 24 hours
post procedure. Vorobeichik et al. (2017) also supported dexmedetomidine as an opioid sparing
technique. They determined that in the 24 hour post-operative period that perineural
dexmedetomidine decreased the oral morphine equivalent consumption by an average of 10.2 mg
(Vorobeichik et al., 2017).
Limitations & Literature Gaps
When comparing the studies above, several limitations are noted: the first is the small
sample sizes. Studies by Manjunatha et al. (2020), Agarwal et al. (2014), and Somsounder et al.
(2019) all enrolled small cohorts with populations of less than 100 participants, making the
results difficult to apply to the public. Other limitations in the data are the variation in technique,
local anesthetics used, and dosing of dexmedetomidine utilized as an adjunct. These noted
variations can produce substantial differences in the data collected as there was no
standardization in study methods across each of the studies included in the literature review.
Many studies focus heavily on the onset and duration of the peripheral nerve block more
than the prolongation of pain control. Several studies touched upon 24-hour post-operative pain
scale ratings and the need for rescue narcotics or analgesics a day out from surgery. Yet, there
was limited data collected about hours zero – 24. The lack evidence makes drawing conclusions
about the efficacy of pain control during the first 24 hours difficult.
Another variable that created a gap in the literature was the local anesthetic used in
brachial plexus blocks. Each study described a different local anesthetic of choice, and
sometimes multiple local anesthetics were examined within a single meta-analysis. Although the
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drug class is the same, the effects of each individual drug may play an influential role in the
effects of adjunct perineural dexmedetomidine.
With less than 100 participants, multiple small studies examined dexmedetomidine as an
adjunct to local anesthetics. These small sample size randomized control trials, each with a
different local anesthetic studied, make the generalizability of the results difficult to apply to all
patient populations. Also, patients enrolled in these trials mainly were ASA class I or II patients
without significant comorbidities. This also makes applying the results to the public difficult as
many patients presenting for surgery often have significant comorbidities. More research is
warranted with larger patient populations and patients with varying ASA classifications to better
understand the use of perineural dexmedetomidine as an opioid/narcotic sparing technique.
Recommendations
The literature supports the use of dexmedetomidine to prolong the duration of sensory
and motor blockade in regional nerve blocks. The data supports the idea that as sensory block is
prolonged, the need for rescue analgesics and opioids in the post-operative period is consistently
reduced when dexmedetomidine is utilized as an adjunct with plain local anesthetics. When
utilized, the most efficacious dose of perineural dexmedetomidine ranges from 50 to 60 mcg,
with the effects being achieved using both weight-based and non-weight-based dosing
calculations (Jung et al., 2017; Vorobeichik et al., 2017; Dai et al., 2018). When examining
current practice, the use of perineural dexmedetomidine does appear to be a viable and effective
adjunct to plain local anesthetics and can pragmatically be utilized as a means of sparing opioids
in the post-operative period.
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Conclusion
Regardless of the chosen technical approach, brachial plexus peripheral nerve blocks are
widely accepted forms of surgical anesthesia and post pain control measures for patients
undergoing upper extremity procedures (Urits et al., 2020; Hewson et al., 2019). Plain, longacting local anesthetics such as 0.5% ropivacaine and 0.5% bupivacaine are often the chosen
agents to provide anesthesia and analgesia for as long as 14 hours after an upper extremity
procedure (Hewson et al., 2019; Ding et al., 2017). As discussed above, dexmedetomidine used
as an adjunct to plain local anesthetics can prolong the analgesic effect of regional nerve blocks
utilized for shoulder surgery by as long as 24 hours. Studies have concluded that including
dexmedetomidine as an adjunct to regional anesthesia has decreased the need for opioids in the
post-operative period by as much as 64% (Trop & McClain, 2020).
By increasing the duration of motor and sensory blockade, perineural dexmedetomidine
extends the pain control benefits on regional blocks utilized for shoulder surgery. The longer the
nerve block lasts, the lesser the need for opioids to help with pain control in the post-operative
period. As the consumption of opioids decreases, the potential risk of suffering adverse reactions
to such medications is also lessened. The literature does support the use of dexmedetomidine as
an adjunct to regional anesthesia and the potential opioid-sparing benefits. However, more
organized research is warranted to support further dexmedetomidine’s effect as an opioid-sparing
technique.
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